Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA543] – NICE

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs. It recommends:  Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA537] – NICE

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults. Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as described in NICE’s technology appraisal

Musculoskeletal core capabilities framework for first point of contact practitioners – Arthritis and Musculoskeletal Alliance

Framework that sets out the essential skills and knowledge necessary for staff with a role as a first point of contact for adults presenting with undiagnosed musculoskeletal conditions. It is relevant to different types of service provision and settings, and

Rheumatoid arthritis in over 16s: Quality standard [QS33] – NICE

This updated quality standard covers the diagnosis and management of rheumatoid arthritis in adults (aged 16 and older). It describes high-quality care in priority areas for improvement.